ImmunityBio Reports Q3 2026 Results: Net Loss of $184. ...
Product Revenue Grows 53% Year-Over-Year as ANKTIVA Label Expands and Global Approvals Reach 35 Countries Related Stocks: IBRX ,
Product Revenue Grows 53% Year-Over-Year as ANKTIVA Label Expands and Global Approvals Reach 35 Countries Related Stocks: IBRX ,